In its latest attempt to build market credibility, China on Monday launched the Science and Technology Innovation Board, or "STAR Market," on which 25 companies were listed.China Economyread more
Stocks in Asia traded lower on Monday morning, as a Nasdaq-style technology board on the Shanghai Stock Exchange marked its debut.Asia Marketsread more
These box office numbers do not include the cost of production or marketing costs. They also don't count the billions in merchandising that Disney has made over the last...Entertainmentread more
When Cathy Hsu and Tony Hsieh wanted to build an English language app for Chinese children, they decided to follow Facebook and Google's lead.Start-upsread more
Tariffs are the only instrument left for addressing China's systematic and excessive surpluses on its U.S. trades, writes Michael Ivanovitch.US Economyread more
Instagram began tests that hide "like" counts on posts. That means influencers who market products on Instagram will have to rely on different metrics to show success.Technologyread more
Peter Neupert worked for Microsoft and Amazon-backed Drugstore.com, where he got to know Jeff Bezos. He now advises start-ups.Technologyread more
The firing of the tear gas was the latest confrontation between police and protesters who have taken to the streets for over a month to fight a proposed extradition bill and...China Politicsread more
Last week shows that oil prices are not the indicator for Middle East tensions they once were, and worries about global demand and growing U.S. production has changed that...Market Insiderread more
Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female corporate-development...Technologyread more
Amazon's new policy for account suspensions doesn't go far enough to protect sellers from potentially unfair and wrongful suspensions, merchants say.Technologyread more
The offer of $235 per share in cash represents a premium of about 68 percent to Loxo's Friday close. Loxo's shares surged 66.2 percent to $232.36 on Monday, while Lilly dropped 1.50 percent to $112.94 a share.
"We'd like to grow our presence in oncology. We have a good set of medicines there but we'd like to expand that because there's so much exciting science for patients emerging in oncology to invest in," Lilly CEO David Ricks told CNBC's Jim Cramer on "Squawk on the Street. "
Lilly said it will update its financial outlook to include the full purchase price of the acquisition when it announces its fourth-quarter earnings in February. The cost of cash was already worked into its guidance for fiscal year 2019.
Last year, U.S. regulators approved Loxo's first commercial medicine, Vitrakvi, which was shown to be effective against a wide variety of cancers driven by a single, rare genetic mutation. The drug is sold in partnership with Bayer.
President of Lilly Oncology Anne White told analysts on a conference call that the company plans to continue that partnership.
"We believe that Lilly will bring a great deal of strength to this partnership in addition to what Loxo has already done," she said.
Loxo Oncology is developing a pipeline of targeted medicines focused on such cancers that can be detected by genomic testing.
Deutsche Bank is Lilly's financial adviser and Weil, Gotshal & Manges is its legal adviser. Goldman Sachs is the financial adviser, while Fenwick & West is legal adviser to Loxo.
—CNBC's Amelia Lucas contributed to this report.